Oral / Subcutaneous · GLP-1 / GIP / glucagon triple
MWN109
12 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
12
Ongoing
6
Recruiting
3
Completed
6
Sites
7
Countries
2
Endpoints
158
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
6
Phase 2
5
Phase 3
1
Trials by status
Not yet recruiting
1
Recruiting
3
Active, not recruiting
2
Completed
6
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
74
Weight & body composition
42
Glycemic / diabetes
18
Cardiometabolic biomarkers
12
Other (unclassified)
10
MASH / liver
1
Renal / kidney
1
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
12 of 12
Showing 1-12 of 12 trials